Teva Pharmaceutical TEVA releases its next round of earnings this Thursday. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report.
Earnings and Revenue
Based on Teva management projections, analysts predict EPS of 64 cents on revenue of $4.74 billion.
Teva EPS in the same period a year ago totaled $1.02. Revenue was $5.69 billion. The analyst consensus estimate would represent a 37.25 percent decrease in the company's earnings. Sales would be down 16.64 percent from the year-ago period. Teva Pharmaceutical Indus's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 0.66 | 0.76 | 1.06 | 1.08 |
| EPS Actual | 0.94 | 0.93 | 1 | 1.02 |
Stock Performance
Over the last 52-week period, shares of Teva have declined 25.97 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release. Long-term shareholders are already wary of 12-month losses prior to the announcement.
Analyst estimates are adjusted lower for EPS and revenues over the past 90 days. Analysts have been rating Teva stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Teva Pharmaceutical's is scheduled to hold a conference call at 8:00 a.m. ET and it can be accessed here: https://digital.vevent.com/index.jsp?eid=7985&seid=1427
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
